AI Article Synopsis
- A study analyzed 120 infants with intestinal failure and a stoma from 2011 to 2020 to assess outcomes following bowel reanastomosis (RA), focusing on enteral autonomy (EA), hospital stay, and mortality rates.
- Key findings revealed that longer intervals between ostomy creation and RA decreased the odds of achieving EA and increased the risk of death, while increased enteral feeding volume improved EA and reduced hospital stay duration.
- The study concluded that minimizing intestinal discontinuity time and enhancing enteral nutrition prior to RA could lead to better outcomes for these infants.
Article Abstract
Background: To determine variables associated with outcomes in infants with intestinal failure (IF) and ostomy following reanastomosis (RA).
Methods: A single-center, descriptive cohort study of 120 infants with IF and a stoma from January 2011 to December 2020 with subsequent RA during initial hospitalization. The primary outcome was achievement of enteral autonomy (EA) following RA. Other outcomes were duration of hospital stay, and mortality. Penalized logistic regression and linear regression were used for data analysis.
Results: The median gestational age was 26 weeks, and the median birth weight was 890 g. Three infants died. The median duration between ostomy creation and RA was 80 days (interquartile range; 62.5, 100.5). For each additional day of discontinuity, the odds of EA decreased by 2% (odds ratio [OR] = 0.980; 95% confidence interval [CI]: 0.962, 0.999; P = 0.038), and death increased by 4.2% (OR = 1.042; 95% CI: 1.010, 1.075; P = 0.009). For each additional mL/kg/day of enteral feeds at RA, the odds of EA increased by 7.5% (OR = 1.075; 95% CI: 1.027, 1.126, P = 0.002) and duration of hospital stay decreased by 0.35 days (slope coefficient = -0.351; 95% CI: -0.540, -0.163; P < 0.001).
Conclusion: Shorter duration of intestinal discontinuity and enteral nutrition before RA could positively influence EA and duration of stay in infants with IF and ostomy following RA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jpen.2570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background And Aims: Glepaglutide is a long-acting GLP-2 analog developed to improve intestinal absorption in short bowel syndrome (SBS) patients. We conducted a trial to establish efficacy and safety of glepaglutide in reducing parenteral support (PS) needs in SBS patients with intestinal failure (IF).
Methods: In an international, placebo-controlled, randomized, parallel-group, double-blind, phase 3 trial, SBS-IF patients requiring PS ≥3 days/week were randomized 1:1:1 to 24 weeks of glepaglutide 10 mg twice-weekly (TW) or once-weekly (OW), or placebo.
Eating behaviors of children with intestinal failure and those who achieve enteral autonomy: An observational cross-sectional study.
Nutr Clin Pract
December 2024
Post-Graduate Program of Child and Adolescent Health, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
Background: Children with intestinal failure (IF) receiving prolonged parenteral nutrition (PN) are exposed to risk factors that predispose them to developing disordered eating behavior. This study aimed to assess the food interest patterns of PN-dependent children with IF and those who achieved enteral autonomy (EA).
Methods: A cross-sectional study was conducted in children aged 1-14 years with IF currently receiving PN for >60 days and in children who achieved EA.
Chronic Intestinal Failure and Short Bowel Syndrome in Adults: The State of the Art.
GE Port J Gastroenterol
December 2024
GENE - Artificial Feeding Team, Gastroenterology Department, Hospital Garcia de Orta, Almada, Portugal.
Background: Short bowel syndrome (SBS) is a devastating malabsorptive condition and the most common cause of chronic intestinal failure (CIF). During the intestinal rehabilitation process, patients may need parenteral support for months or years, parenteral nutrition (PN), or hydration/electrolyte supplementation, as a bridge for the desired enteral autonomy.
Summary: Several classification criteria have been highlighted to reflect different perspectives in CIF.
Use of glucagon-like polypeptide 2 analogs for intestinal failure.
Expert Opin Pharmacother
December 2024
Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Introduction: Over a half century ago, a component of glucagon was found to have potent gastrointestinal effects. Shortly after proglucagon was sequenced, its component peptides were characterized, and glucagon-like polypeptide-2 (GLP-2) was noted to have the most potent intestinotrophic properties improving fluid and electrolyte balance in experimental animals and humans.
Areas Covered: Glucagon-like polypeptide-1 (GLP-1) slows small intestinal motility more effectively, but its intestinotrophic properties are weaker.
Parenteral nutrition dependence and growth in pediatric patients with intestinal failure following transition to blenderized tube feedings: A case series.
Nutr Clin Pract
November 2024
Center for Advanced Intestinal Rehabilitation, Boston Children's Hospital, Boston, Massachusetts, USA.
Article Synopsis
- * Twelve children met the criteria for the study, with most having undergone small bowel resection; after the switch to BTF, 25% achieved enteral autonomy, and 58% showed a decrease in PN energy intake.
- * The transition to BTF did not significantly alter growth patterns or stool frequency, suggesting that BTF can be a beneficial option for older children with IF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!